Bioengineering approaches to study multidrug resistance in tumor cells

Integrative Biology

Volumn 3, Issue 5, 2011, Pages 529-539

  Fallica, Brian ^a   Makin, Guy ^b   Zaman, Muhammad H ^a  

^a Boston University   (United States)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; TIRAPAZAMINE;

APOPTOSIS; BIOENGINEERING; BIOLUMINESCENCE; CANCER CELL; CANCER RESISTANCE; CANCER STEM CELL; CELL ADHESION; CELL HYPOXIA; DNA REPAIR; DRUG DETOXIFICATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MULTIDRUG RESISTANCE; NEOPLASM; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR MICROENVIRONMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMEDICAL ENGINEERING; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, MULTIPLE; HUMANS; NEOPLASMS;

EID: 79959537229     PISSN: 17579694     EISSN: 17579708     Source Type: Journal    
DOI: 10.1039/c0ib00142b     Document Type: Review

References (126)

1. M. Heron, D. L. Hoyert and S. L. Murphy, et al., Deaths: final data for 2006, Natl. Vital Stat. Rep., 2009, 57, 1-134.
2. P. Mehlen and A. Puisieux, Metastasis: a question of life or death, Nat. Rev. Cancer, 2006, 6, 449-458.
3. E. Frei, E. J. Freireich and E. Gehan, et al., Studies of sequential and combination antimetabolite therapy in acute leukemia: 6-mercaptopurine and methotrexate, Blood, 1961, 18, 431-454.
4. M. L. Maitland and M. J. Ratain, Terminal ballistics of kinase inhibitors: there are no magic bullets, Ann. Intern. Med., 2006, 145, 702-703.
5. G. V. Denis, Imatinib mesylate (Gleevec®) and the emergence of chemotherapeuticss drug-resistant mutations, Mol. Target. Oncol., 2008, 545-558.
6. A. W. Hamburger and S. E. Salmon, Primary bioassay of human tumor stem cells, Science, 1977, 197, 461-463.
7. T. Reya, S. J. Morrison, M. F. Clarke and I. L. Weissman, Stem cells, cancer, and cancer stem cells, Nature, 2001, 414, 105-111.
8. M. Mimeault and S. K. Batra, Concise review: recent advances on the significance of stem cells in tissue regeneration and cancer therapies, Stem Cells, 2006, 24, 2319-2345.
9. M. Mimeault and S. K. Batra, Interplay of distinct growth factors during epithelial-mesenchymal transition of cancer progenitor cells and molecular targeting as novel cancer therapies, Ann. Oncol., 2007, 18, 1605-1619. (Pubitemid 47506246)
10. M. S. Wicha, S. Liu and G. Dontu, Cancer stem cells: an old idea - a paradigm shift, Cancer Res., 2006, 66, 1883-1890.
11. G. Liu, X. Yuan and Z. Zeng, et al., Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma, Mol. Cancer, 2006, 5, 67.
12. M. Mimeault, R. Hauke and S. Batra, Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies, Clin. Pharmacol. Ther., 2007, 83, 673-691.
13. M. Dean, T. Fojo and S. Bates, Tumour stem cells and drug resistance, Nat. Rev. Cancer, 2005, 5, 275-284. (Pubitemid 40488633)
14. M. Zhang and J. M. Rosen, Stem cells in the etiology and treatment of cancer, Curr. Opin. Genet. Dev., 2006, 16, 60-64.
15. T. M. Phillips, W. H. McBride and F. Pajonk, The response of CD24-/low/CD44+ breast cancer-initiating cells to radiation, J. Natl. Cancer Inst., 2006, 98, 1777-1785. (Pubitemid 46017929)
16. F. Ravandi and Z. Estrov, Eradication of leukemia stem cells as a new goal of therapy in leukemia, Clin. Cancer Res., 2006, 12, 340-344. (Pubitemid 43166119)
17. M. A. Huber, N. Kraut and H. Beug, Molecular requirements for epithelial-mesenchymal transition during tumor progression, Curr. Opin. Cell Biol., 2005, 17, 548-558. (Pubitemid 41267170)
18. R. Mick, J. J. Crowley and R. J. Carroll, Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint, Controlled Clin. Trials, 2000, 21, 343-359. (Pubitemid 30456294)
19. C. Sotiriou and M. J. Piccart, Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?, Nat. Rev. Cancer, 2007, 7, 545-553.
20. F. Li, B. Tiede, J. Massague and Y. Kang, Beyond tumorigenesis: cancer stem cells in metastasis, Cell Res., 2007, 17, 3-14. (Pubitemid 46096419)
21. E. Galmozzi, F. Facchetti and C. L. Porta, Cancer stem cells and therapeutic perspectives, Curr. Med. Chem., 2006, 13, 603-607.
22. G. Zhou, J. Zhang, Z. Wang, S. Chen and Z. Chen, Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy, Philos. Trans. R. Soc. London, Ser. B, 2007, 362, 959-971.
23. M. W. Dewhirst, Concepts of oxygen transport at the micro-circulatory level, Semin. Radiat. Oncol., 1998, 8, 143-150.
24. J. M. Brown and W. R. Wilson, Exploiting tumour hypoxia in cancer treatment, Nat. Rev. Cancer, 2004, 4, 437-447.
25. P. Baluk, S. Morikawa, A. Haskell, M. Mancuso and D. M. McDonald, Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors, Am. J. Pathol., 2003, 163, 1801-1815. (Pubitemid 37310012)
26. P. Subarsky and R. Hill, The hypoxic tumour microenvironment and metastatic progression, Clin. Exp. Metastasis, 2003, 20, 237-250. (Pubitemid 36513228)
27. G. L. Smoron, Radiobiology for the radiologist, Am. J. Roentgenol., 2002, 178, 600.
28. P. H. Maxwell, C. W. Pugh and P. J. Ratcliffe, Activation of the HIF pathway in cancer, Curr. Opin. Genet. Dev., 2001, 11, 293-299.
29. B. Krishnamachary, S. Berg-Dixon and B. Kelly, et al., Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1, Cancer Res., 2003, 63, 1138-1143. (Pubitemid 36278449)
30. D. Hussein, E. J. Estlin, C. Dive and G. W. J. Makin, Chronic hypoxia promotes hypoxia-inducible factor-1α-dependent resistance to etoposide and vincristine in neuroblastoma cells, Mol. Cancer Ther., 2006, 5, 2241-2250. (Pubitemid 44530461)
31. J. T. Erler, C. J. Cawthorne and K. J. Williams, et al., Hypoxia-mediated down-regulation of bid and bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance, Mol. Cell. Biol., 2004, 24, 2875-2889.
32. M. Kilic, H. Kasperczyk, S. Fulda and K. Debatin, Role of hypoxia inducible factor-1 alpha in modulation of apoptosis resistance, Oncogene, 2006, 26, 2027-2038.
33. L. M. Brown, R. L. Cowen and C. Debray, et al., Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1, Mol. Pharmacol., 2006, 69, 411-418. (Pubitemid 43121938)
34. D. R. Gandara, P. N. Lara and Z. Goldberg, et al., Tirapazamine: prototype for a novel class of therapeutic agents targeting tumor hypoxia, Semin. Oncol., 2002, 29, 102-109. (Pubitemid 34226525)
35. G. L. Semenza, Targeting HIF-1 for cancer therapy, Nat. Rev. Cancer, 2003, 3, 721-732.
36. G. Melillo, Inhibiting hypoxia-inducible factor 1 for cancer therapy, Mol. Cancer Res., 2006, 4, 601-605. (Pubitemid 44497213)
37. R. Tibes, G. S. Falchook and D. D. Von Hoff, et al., Results from a phase I, dose-escalation study of PX-478, an orally available inhibitor of HIF-1 alpha, J. Clin. Oncol. (Meeting Abstracts)., 2010, 28, 3076.
38. W. S. Dalton, The tumor microenvironment as a determinant of drug response and resistance, Drug Resist. Updates, 1999, 2, 285-288.
39. S. Green, A. Frankel and R. Kerbel, Adhesion-dependent multicellular drug resistance, Anti-Cancer Drug Des., 1999, 14, 153-168. (Pubitemid 29292312)
40. R. M. Sutherland and R. E. Durand, Cell contact as a possible contribution to radiation resistance of some tumours, Br. J. Radiol., 1972, 45, 788-789.
41. B. S. Croix, J. W. Rak and S. Kapitain, et al., Reversal by hyaluronidase of adhesion-dependent multicellular drug resistance in mammary carcinoma cells, J. Natl. Cancer Inst., 1996, 88, 1285-1296. (Pubitemid 26301616)
42. A. Frankel, R. Buckman and R. S. Kerbel, Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids, Cancer Res., 1997, 57, 2388-2393.
43. M. Faute, L. Laurent and D. Ploton, et al., Distinctive alterations of invasiveness, drug resistance and cell-cell organization in 3d-cultures of MCF-7, a human breast cancer cell line, and its multidrug resistant variant, Clin. Exp. Metastasis, 2002, 19, 161-167.
44. H. Kobayashi, S. Man and C. H. Graham, et al, Acquired multicellular-mediated resistance to alkylating agents in cancer, Proc. Natl. Acad. Sci. U. S. A., 1993, 90, 3294-3298.
45. S. K. Green, G. Francia, C. Isidoro and R. S. Kerbel, Antiadhesive antibodies targeting E-cadherin sensitize multicellular tumor spheroids to chemotherapy in vitro, Mol. Cancer Ther., 2004, 3, 149-159. (Pubitemid 39193689)
46. R. D. Baird and S. B. Kaye, Drug resistance reversal - are we getting closer?, Eur. J. Cancer, 2003, 39, 2450-2461. (Pubitemid 37340159)
47. R. C. Bates, N. S. Edwards, G. F. Burns and D. E. Fisher, A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3-kinase/AKT in colon carcinoma cells, Cancer Res., 2001, 61, 5275-5283.
48. R. Wu, Z. Wang, M. Liu, D. Chen and X. Yue, β2-Integrins mediate a novel form of chemoresistance in cycloheximide-induced U937 apoptosis, Cell. Mol. Life Sci., 2004, 61, 2071-2082. (Pubitemid 39149896)
49. Y. Matsumura and D. Tarin, Significance of CD44 gene products for cancer diagnosis and disease evaluation, Lancet, 1992, 340, 1053-1058.
50. S. M. Frisch and R. A. Screaton, Anoikis mechanisms, Curr. Opin. Cell Biol., 2001, 13, 555-562.
51. T. Sethi, R. C. Rintoul and S. M. Moore, et al., Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo, Nat. Med., 1999, 5, 662-668. (Pubitemid 29289430)
52. J. S. Damiano, Integrins as novel drug targets for overcoming innate drug resistance, Curr. Cancer Drug Targets, 2002, 2, 37-43.
53. M. Dean, Y. Hamon and G. Chimini, The human ATP-binding cassette (ABC) transporter superfamily, J. Lipid Res., 2001, 42, 1007-1017. (Pubitemid 32645780)
54. J. Gillet and M. M. Gottesman, Mechanisms of multidrug resistance in cancer, Multi-Drug Res. Cancer., 2010, 596, 47-76.
55. K. Ueda, C. Cardarelli, M. M. Gottesman and I. Pastan, Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine, Proc. Natl. Acad. Sci. U. S. A., 1987, 84, 3004-3008.
56. R. Juliano and V. Ling, A surface glycoprotein modulating drug permeability in chinese hamster ovary cell mutants, Biochim. Biophys. Acta, Biomembr., 1976, 455, 152-162.
57. K. Takara, T. Sakaeda and K. Okumura, An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy, Curr. Pharm. Des., 2006, 12, 273-286.
58. Q. Mao, Role of the breast cancer resistance protein (ABCG2) in drug transport, AAPS J., 2005, 7, E118-E133. (Pubitemid 41554295)
59. M. M. Gottesman, T. Fojo and S. E. Bates, Multidrug resistance in cancer: role of atp-dependent transporters, Nat. Rev. Cancer, 2002, 2, 48-58.
60. R. G. Deeley, C. Westlake and S. P. C. Cole, Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins, Physiol. Rev., 2006, 86, 849-899.
61. E. E. Pakos and J. P. A. Ioannidis, The association of p-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma, Cancer, 2003, 98, 581-589.
62. K. Patel and I. Tannock, The influence of p-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors, BMC Cancer, 2009, 9, 356.
63. F. Morschhauser, P. L. Zinzani and M. Burgess, et al., Phase I/II trial of a p-glycoprotein inhibitor, zosuquidar·3HCl trihydrochloride (LYly335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma, Leuk. Lymphoma, 2007, 48, 708-715. (Pubitemid 46605542)
64. M. M. O'Brien, N. J. Lacayo and B. L. Lum, et al., Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the children's oncology group, Pediatr. Blood Cancer, 2010, 54, 694-702.
65. M. Werle, H. Takeuchi and A. Bernkop-Schnürch, Newgeneration efflux pump inhibitors, Expert Rev. Clin. Pharmacol., 2008, 1, 429-440.
66. A. F. List, K. J. Kopecky and C. L. Willman, et al., Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a southwest oncology group study, Blood, 2001, 98, 3212-3220.
67. A. Lockhart, R. Bukowski and M. Rothenberg, et al., Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors, Cancer Chemother. Pharmacol., 2007, 60, 203-209. (Pubitemid 46742535)
68. L. E. Bröker, S. A. Veltkamp and E. I. Heath, et al., A phase I safety and pharmacologic study of a twice weekly dosing regimen of the oral taxane BMS-275183, Clin. Cancer Res., 2007, 13, 3906-3912. (Pubitemid 47037598)
69. V. Diéras, S. Limentani and G. Romieu, et al., Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy, Ann. Oncol., 2008, 19, 1255-1260. (Pubitemid 351911954)
70. D. C. Altieri, Survivin, versatile modulation of cell division and apoptosis in cancer, Oncogene, 2003, 22, 8581-8589.
71. O. Micheau, M. Thome and P. Schneider, et al., The long form of flip is an activator of caspase-8 at the Fas death-inducing signaling complex, J. Biol. Chem., 2002, 277, 45162-45171. (Pubitemid 36159119)
72. R. J. Youle and A. Strasser, The Bcl-2 protein family: opposing activities that mediate cell death, Nat. Rev. Mol. Cell Biol., 2008, 9, 47-59.
73. H. L. Galonek and J. M. Hardwick, Upgrading the Bcl-2 network, Nat. Cell Biol., 2006, 8, 1317-1319. (Pubitemid 44835103)
74. D. Hanahan and R. A. Weinberg, The hallmarks of cancer, Cell, 2000, 100, 57-70.
75. S. M. O'Brien, D. F. Claxton and M. Crump, et al, Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia, Blood, 2009, 113, 299-305.
76. S. O'Brien, J. O. Moore and T. E. Boyd, et al., Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia, J. Clin. Oncol., 2007, 25, 1114-1120. (Pubitemid 46596764)
77. V. J. Spanswick, C. Craddock and M. Sekhar, et al., Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma, Blood, 2002, 100, 224-229. (Pubitemid 35177451)
78. S. W. Johnson, P. B. Laub, J. S. Beesley, R. F. Ozols and T. C. Hamilton, Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines, Cancer Res., 1997, 57, 850-856.
79. O. I. Olopade and M. Wei, Fancf methylation contributes to chemoselectivity in ovarian cancer, Cancer Cell, 2003, 3, 417-420. (Pubitemid 38340287)
80. A. S. Balajee, M. Bogliolo and J. Surrallés, The Fanconi anemia/BRCA pathway, DNA Rep. Human Dis., 2006, 67-81.
81. D. Durocher and S. P. Jackson, DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme?, Curr. Opin. Cell Biol., 2001, 13, 225-231.
82. C. Muller, G. Christodoulopoulos, B. Salles and L. Panasci, DNA-dependent protein kinase activity correlates with clinical and in vitro sensitivity of chronic lymphocytic leukemia lymphocytes to nitrogen mustards, Blood, 1998, 92, 2213-2219. (Pubitemid 28452960)
83. P. Karran, Mechanisms of tolerance to dna damaging therapeutic drugs, Carcinogenesis, 2001, 22, 1931-1937. (Pubitemid 34065386)
84. A. Vaisman, M. Varchenko and A. Umar, et al., The role of HMHLA1, HMSH3, and HMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-dna adducts, Cancer Res., 1998, 58, 3579-3585.
85. S. L. Gerson, Mgmt: its role in cancer aetiology and cancer therapeutics, Nat. Rev. Cancer, 2004, 4, 296-307.
86. A. Maxmen, Beyond PARP inhibitors: agents in pipelines target dna repair mechanisms, J. Natl. Cancer Inst., 2010, 102, 1110-1111.
87. M. Rouleau, A. Patel, M. J. Hendzel, S. H. Kaufmann and G. G. Poirier, PARP inhibition: PARP1 and beyond, Nat. Rev. Cancer, 2010, 10, 293-301.
88. Audeh et al., Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer, 2009, ASCO meeting abstracts, 27(15), 5500.
89. Isakoff et al., A phase II trial of the parp inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer, 2010, ASCO meeting abstracts, 28(15), 1019.
90. D. M. Townsend and K. D. Tew, The role of glutathione-S-transferase in anti-cancer drug resistance, Oncogene, 2003, 22, 7369-7375.
91. S. L. Kelley, A. Basu and B. A. Teicher, et al., Overexpression of metallothionein confers resistance to anticancer drugs, Science, 1988, 241, 1813-1815.
92. H. Rugstad, Metallothionein - a unique protein with multiple detoxifying properties?, Eur. Surg. Res., 1984, 16, 102-112. (Pubitemid 14133835)
93. Y. Hishikawa, S. Abe and S. Kinugasa, et al., Overexpression of metallothionein correlates with chemoresistance to cisplatin and prognosis in esophageal cancer, Oncology, 1997, 54, 342-347. (Pubitemid 27252732)
94. K. D. Tew, Glutathione-associated enzymes in anticancer drug resistance, Cancer Res., 1994, 54, 4313-4320.
95. C. Peklak-Scott, A. J. Townsend and C. S. Morrow, Dynamics of glutathione conjugation and conjugate efflux in detoxification of the carcinogen, 4-nitroquinoline 1-oxide: contributions of glutathione, glutathione-S- transferase, and MRPL, Biochemistry, 2005, 44, 4426-4433.
96. P. J. O'Dwyer, F. LaCreta and S. Nash, et al., Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid, Cancer Res., 1991, 51, 6059-6065.
97. I. Vergote, N. J. Finkler and J. B. Hall, et al., Randomized phase III study of canfosfamide (C, TLK286) plus pegylated liposomal doxorubicin (pld) versus pld as second-line therapy in platinum (P) refractory or resistant ovarian cancer (OC), J. Clin. Oncol. (Meeting Abstracts)., 2009, 27, 5552.
98. H. Chakrapani, T. C. Wilde and M. L. Citro, et al., Synthesis, nitric oxide release, and anti-leukemic activity of glutathione-activated nitric oxide prodrugs: structural analogues of PABA/NO, an anti-cancer lead compound, Bioorg. Med. Chem., 2008, 16, 2657-2664.
99. L. G. Griffith and M. A. Swartz, Capturing complex 3d tissue physiology in vitro, Nat. Rev. Mol. Cell Biol., 2006, 7, 211-224.
100. J. L. Horning, S. K. Sahoo and S. Vijayaraghavalu, et al., 3-d tumor model for in vitro evaluation of anticancer drugs, Mol. Pharmaceutics, 2008, 5, 849-862.
101. W. M. van Weerden and J. C. Romijn, Use of nude mouse xenograft models in prostate cancer research, Prostate, 2000, 43, 263-271.
102. T. Blunt, N. J. Finnie and G. E. Taccioli, et al., Defective DNA-dependent protein kinase activity is linked to V(D)J recombination and DNA repair defects associated with the murine scid mutation, Cell, 1995, 80, 813-823.
103. M. G. Pomper, Can small animal imaging accelerate drug development?, J. Cell. Biochem., 2002, 87, 211-220.
104. N. E. Sharpless and R. A. DePinho, The mighty mouse: genetically engineered mouse models in cancer drug development, Nat. Rev. Drug Discovery, 2006, 5, 741-754.
105. C. S. Chen, M. Mrksich, S. Huang, G. M. Whitesides and D. E. Ingber, Geometric control of cell life and death, Science, 1997, 276, 1425-1428.
106. J. Xu and R. A. Clark, Extracellular matrix alters PDGF regulation of fibroblast integrins, J. Cell Biol., 1996, 132, 239-249.
107. C. M. Nelson and C. S. Chen, Cell-cell signaling by direct contact increases cell proliferation via a PI3K-dependent signal, FEBS Lett., 2002, 514, 238-242.
108. X. Zhu, M. Ohtsubo, R. M. Böhmer, J. M. Roberts and R. K. Assoian, Adhesion-dependent cell cycle progression linked to the expression of cyclin D1, activation of cyclin E-CDK2, and phosphorylation of the retinoblastoma protein, J. Cell Biol., 1996, 133, 391-403.
109. S. Huang, C. S. Chen and D. E. Ingber, Control of cyclin D1, P27Kip1, and cell cycle progression in human capillary endothelial cells by cell shape and cytoskeletal tension, Mol. Biol. Cell., 1998, 9, 3179-3193.
110. M. Ochsner, M. R. Dusseiller and H. M. Grandin, et al., Micro-well arrays for 3d shape control and high resolution analysis of single cells, Lab Chip, 2007, 7, 1074-1077.
111. M. Hakanson, M. Textor and M. Charnley, Engineered 3d environments to elucidate the effect of environmental parameters on drug response in cancer, Integr. Biol., 2011, 3, 31-38.
112. W. Knudson, C. Biswas and B. P. Toole, Interactions between human tumor cells and fibroblasts stimulate hyaluronate synthesis, Proc. Natl. Acad. Sci. U. S. A., 1984, 81, 6767-6771. (Pubitemid 15221001)
113. Y. Iwai, M. Ishida and Y. Tanaka, et al., Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade, Proc. Natl. Acad. Sci. U. S. A., 2002, 99, 12293-12297.
114. C. C. Lynch and L. M. Matrisian, Matrix metalloproteinases in tumor-host cell communication, Differentiation, 2002, 70, 561-573.
115. A. Wenger, A. Stahl and H. Weber, et al., Modulation of in vitro angiogenesis in a three-dimensional spheroidal coculture model for bone tissue engineering, Tissue Eng., 2010, 10, 1536-1547.
116. R. N. Bhandari, L. A. Riccalton and A. L. Lewis, et al., Liver tissue engineering: a role for co-culture systems in modifying hepatocyte function and viability, Tissue Eng., 2001, 7, 345-357.
117. Y. ZHANG, B. P. KROPP and P. MOORE, et al., Coculture of bladder urothelial and smooth muscle cells on small intestinal submucosa: potential applications for tissue engineering technology, J. Urol., 2000, 164, 928-935.
118. L. Zhong, J. Roybal and R. Chaerkady, et al., Identification of secreted proteins that mediate cell-cell interactions in an in vitro model of the lung cancer microenvironment, Cancer Res., 2008, 68, 7237-7245.
119. K. Schiller, M. Zillhardt and J. Alley, et al., Secretion of MCP-1 and other paracrine factors in a novel tumor-bone coculture model, BMC Cancer, 2009, 9, 45.
120. C. Eng, G. Leone, M. S. Orloff and M. C. Ostrowski, Genomic alterations in tumor stroma, Cancer Res., 2009, 69, 6759-6764.
121. B. M. Veneziani, V. Criniti and C. Cavaliere, et al., In vitro expansion of human breast cancer epithelial and mesenchymal stromal cells: optimization of a coculture model for personalized therapy approaches, Mol. Cancer Ther., 2007, 6, 3091-3100.
122. D. W. McMillin, J. Delmore and E. Weisberg, et al., Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity, Nat. Med., 2010, 16, 483-489.
123. M. H. Flight, Drug screening: shedding light on tumour-stroma interactions, Nat. Rev. Drug Discovery, 2010, 9, 360-361.
124. S. Loges, T. Schmidt and P. Carmeliet, Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates, Genes Cancer, 2010, 1, 12-25.
125. Z. Yao, S. Fenoglio and D. C. Gao, et al., TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer, Proc. Natl. Acad. Sci. U. S. A., 2010, 107, 15535-15540.
126. I. Barone, Y. Cui and M. H. Herynk, et al., Expression of the K303R estrogen receptor-a breast cancer mutation induces resistance to an aromatase inhibitor via addiction to the PI3K/AKT kinase pathway, Cancer Res., 2009, 69, 4724-4732.